原发性中枢神经系统淋巴瘤诊治现状及进展

doi:10.6040/j.issn.1671-7554.0.2019.204

Abstract

Abstract: Primary central nervous system lymphoma(PCNSL)is a rare group of extra-nodal non-Hodgkin lymphoma with specific biological characteristics and clinical behaviors. The systemic chemotherapy based on high-dose methotrexate has improved the clinic outcomes, but risk of relapse and tolerance is still substantial. In this paper, 山东大学学报 (医学版)57卷7期 -周道斌,等.原发性中枢神经系统淋巴瘤诊治现状及进展 \=-we will review the status of diagnosis and treatment of PCNSL, especially advances in the diagnosis, molecular pathogenesis and novel agents in relapsed/refractory cases.

Key words: Primary central nervous system lymphoma, Molecular pathogenesis, Novel agents

CLC Number:

R733.4

ZHOU Daobin, ZHANG Yan. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis and treatment[J].Journal of Shandong University (Health Sciences), 2019, 57(7): 31-39.

References

[1] Villano JL, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma [J]. Br J Cancer, 2015, 105(9): 1414-1418.
[2] Rubenstein JL, Gupta NK, Mannis GN, et al. How I treat CNS lymphomas [J]. Blood, 2013, 122(14): 2318-2330.
[3] Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases [J]. J Neurosurg, 2000, 92(2): 261-266.
[4] 佘春华, 谈丽彩, 李鹏, 等. 30例原发性中枢神经系统淋巴瘤患者的临床特征及预后分析[J]. 中华血液学杂志, 2015, 36(4): 282-285. SHE Chunhua,TAN Licai,LI Peng,et al.Clinical and prognostic analysis of 30 cases of primary central nervous system lymphoma [J].Chinese Journal of Hematology, 2015, 36(4): 282-285.
[5] 朱铁楠, 王书杰, 张薇, 等. 37例原发中枢神经系统淋巴瘤患者的临床特征及预后分析[J]. 中华血液学杂志, 2015, 36(10): 849-852. ZHU Tienan, WANG Shujie, ZHANG Wei, et al. Clinical characteristics and outcome of patients with primary central nervous system lymphoma [J]. Chinese Journal of Hematology, 2015, 36(10): 849-852.
[6] 刘玲, 肖家和, 魏懿, 等. 原发性中枢神经系统淋巴瘤的MRI影像诊断及病理特点[J]. 中国医学影像学杂志, 2011, 19(1): 43-47. LIU Ling, XIAO Jiahe, Wei Yi, et al. MRI diagnosis of primary central nervous system lymphomasand pathological features [J]. Chinese Journal of Medical Imaging, 2011, 19(1): 43-47.
[7] Küker W, Nägele T, Korfel A, et al. Primary central nervous system lymphomas(PCNSL): MRI features at presentation in 100 patients [J]. J Neurooncol, 2005, 72(2): 169-177.
[8] Zou Y, Tong J, Leng H, et al. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis [J]. Oncotarget, 2017, 8(25): 41518-41528.
[9] Jo JC, Yoon DH, Kim S, et al. Interim(18)F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine [J]. Ann Hematol, 2017, 96(9): 1509-1515.
[10] Birsen R, Blanc E, Willems L, et al. Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients [J]. Oncotarget, 2018, 9(24): 16822-16831.
[11] Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma [J]. J Clin Oncol, 2008, 26(1): 96-105.
[12] Rubenstein JL, Wong VS, Kadoch C, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma [J]. Blood, 2013, 121(23): 4740-4748.
[13] Song Y,Zhang W,Zhang L,et al.Cerebrospinal fluid IL-10 and IL-10/IL-6 as accurate diagnostic biomarkers for primary central nervous system large B-cell lymphoma [J]. Sci Rep, 2016, 6: 38671. doi: 10.1038/srep-38671.
[14] Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, et al. Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities [J]. Crit Rev Oncol Hematol, 2018, 127: 56-65. doi: 10.1016/j.critrevonc.
[15] Pentsova EI, Shah RH, Tang J, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid [J]. J Clin Oncol, 2016, 34(20): 2404-2415.
[16] Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, et al. The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P)detection in cerebrospinal fluid [J]. Hematol Oncol, 2018, 36(2): 429-435.
[17] Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma [J]. Blood, 2019, 133(5): 436-445.
[18] Lossos C, Bayraktar S, Weinzierl E, et al. LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma [J]. Br J Haematol, 2014, 165(5): 640-648.
[19] Kim S, Nam SJ, Kwon D, et al. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system [J]. BMC Cancer, 2016, 16: 363. doi:10.1186/s12885-016-2397-8.
[20] Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202(Alliance 50202)[J]. J Clin Oncol, 2013, 31(25): 3061-3068.
[21] Gonzalez-Aguilar A, Idbaih A, Boisselier B, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas [J]. Clin Cancer Res, 2012, 18(19): 5203-5211.
[22] Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas [J]. Blood, 2016, 127(7): 869-881.
[23] Braggio E,Van Wier S, Ojha J,et al.Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas [J]. Clin Cancer Res, 2015, 21(17): 3986-3994.
[24] Hattori K, Sakata-Yanagimoto M, Okoshi Y, et al. MYD88(L265P)mutation is associated with an unfavourable outcome of primary central nervous system lymphoma [J]. Br J Haematol, 2017, 177(3): 492-494.
[25] Todorovic Balint M, Jelicic J, Mihaljevic B, et al. Gene mutation profiles in primary diffuse large b cell lymphoma of central nervous system: next generation sequencing analyses [J]. Int J Mol Sci, 2016, 17(5): 683.
[26] Sung CO, Kim SC, Karnan S,et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma [J]. Blood, 2011, 117(4): 1291-1300.
[27] Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience [J]. J Clin Oncol, 2003, 21(2): 266-272.
[28] Weller M, Martus P, Roth P,et al. Surgery for primary CNS lymphoma? Challenging a paradigm [J]. Neuro Oncol, 2012, 14(12): 1481-1484.
[29] Nelson DF,Martz KL,Bonner H,et al. Non- Hodgkins lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group(RTOG): RTOG 8315 [J]. Int J Radiat Oncol Biol Phys, 1992, 23(1): 9-17.
[30] Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma [J]. J Clin Oncol, 1998, 16(3): 859-863.
[31] Fine HA, Mayer RJ. Primary central nervous system lymphoma [J]. Ann Intern Med, 1993, 119(11): 1093-1104.
[32] Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma [J]. J Clin Oncol, 2007, 25(30): 4730-4735.
[33] Ervin T, Canellos GP. Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate [J]. Cancer, 1980, 45(7): 1556-1557.
[34] Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? [J]. J Clin Oncol, 1998, 16(4): 1561-1567.
[35] Khan RB, Shi W, Thaler HT, et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? [J]. J Neuro oncol, 2002, 58(2): 175-178.
[36] Batchelor T, Carson K, ONeill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07 [J]. J Clin Oncol, 2003, 21(6): 1044-1049.
[37] Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate [J]. Int J Radiat Oncol Biol Phys, 2001, 51(2): 419-425.
[38] Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial [J]. Lancet, 2009, 374(9700): 1512-1520.
[39] Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab(MATRix regimen)in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32(IELSG32)phase 2 trial [J]. Lancet Haematol, 2016, 3(5): 217-227.
[40] DeAngelis LM, Seiferheld W, Schold SC, et al, Radiation Therapy Oncology Group S. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10 [J]. J Clin Oncol, 2002, 20(24): 4643-4648.
[41] Kurzwelly D, Glas M, Roth P, et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status [J]. J Neurooncol, 2010, 97(3): 389-392.
[42] Makino K, Nakamura H, Hide T, et al. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status [J]. J Neurooncol, 2012, 106(1): 155-160.
[43] Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial [J]. Lancet Haematol, 2015, 2(6): 251-259.
[44] Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma [J]. Neurology, 2011, 76(10): 929-930.
[45] Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma [J]. Neurology, 2014, 83(3): 235-239.
[46] Bromberg JEC, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma(HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study [J]. Lancet Oncology, 2019, 20(2): 216-228.
[47] Rubenstein JL, Li J, Chen L, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma [J]. Blood, 2013, 121(5): 745-751.
[48] Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma(G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial [J]. Lancet Oncol, 2010, 11(11): 1036-1047.
[49] Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome [J]. J Clin Oncol, 2013, 31(31): 3971-3979.
[50] Adhikari N, Biswas A, Gogia A, et al. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome [J]. J Neurooncol, 2018, 139(1): 153-166.
[51] Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma [J]. Blood, 2015,125(9): 1403-1410.
[52] Illerhaus G, Kasenda B, Ihorst G, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial [J]. Lancet Haematol, 2016, 3(8): 388-397.
[53] DeFilipp Z, Li S, El-Jawahri A, et al. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission [J]. Cancer, 2017,123(16): 3073-3079.
[54] Ferreri AJM, Pulczynski E. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial [J]. Lancet Haematol, 2017, 4(11): 510-523.
[55] Schorb E, Fox CP, Fritsch K, et al. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study [J]. Bone Marrow Transplant, 2017, 52(8): 1113-1119.
[56] Kassam S, Chernucha E, ONeill A, et al. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom [J]. Bone Marrow Transplant, 2017, 52(9): 1268-1272.
[57] Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma [J]. Blood Adv, 2018, 2(13): 1595-1607.
[58] Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab(revri)in relapsed/refractory primary cns lymphoma or primary intraocular lymphoma: a multicenter prospective “proof of concept” phase ii study of the french oculo-cerebral lymphoma(loc)network and the lymphoma study association(LYSA)[J]. Ann Oncol, 2019, 30(4): 621-628.
[59] Vu K, Mannis G, Hwang J, et al. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma [J]. Br J Haematol, 2019, 186(1): 180-183.
[60] Terziev D, Hutter B, Klink B, et al. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma [J]. Eur J Haematol, 2018, 101(1): 115-118.
[61] Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate [J]. Clin Cancer Res, 2004, 10(17): 5643-5646.
[62] Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire [J]. J Clin Oncol, 2008, 26(15): 2512-2518.
[63] Kasenda B, Schorb E, Fritsch K, et al. Primary CNS lymphoma—radiation-free salvage therapy by second autologous stem cell transplantation [J]. Biol Blood Marrow Transplant, 2011, 17(2): 281-283.
[64] Houillier C, Choquet S, Touitou V, et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma[J]. Neurology, 2015, 84(3): 325-326.
[65] Tun HW, Johnston PB, DeAngelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma[J]. Blood, 2018, 132(21): 2240-2248.
[66] Chamoun K, Choquet S, Boyle E, et al. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series[J]. Neurology, 2017, 88(1): 101-102.
[67] Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma[J]. Cancer Cell, 2017, 31(6): 833-843.
[68] Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma [J]. Blood, 2017, 129(23): 3071-3073.
[69] Löw S, Han CH, Batchelor TT. Primary central nervous system lymphoma[J]. Ther Adv Neurol Disord, 2018, 11: 1756286418793562. doi: 10.1177/1756286418793562.
[70] Kasenda B, Ferreri AJM, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma(PCNSL)—a systematic review and individual patient data meta-analysis[J]. Ann Oncol, 2015, 26(7): 1305-1313.
[71] Fritsch K, Kasenda B, Hader C, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma(PCNSL)in the elderly [J]. Ann Oncol, 2011, 22(9): 2080-2085.
[72] Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients(PRIMAIN study)[J]. Leukemia, 2017, 31(4): 846-852.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 0

No Suggested Reading articles found!

Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis and treatment

PDF (PC)

Abstract

Cite this article

share this article

References

Related Articles 6

Metrics

Comments

Recommended 0

[1]	LI Wensheng. Presentation of the concept of “benign lymphoma” and the discussion of the possibility of its existence [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 1-5.
[2]	SONG Ai-qin1,2, JU Xiu-li1, SUN Li-rong2, WANG Ling-zhen2, LI Xiao-ling2, YU Hong-sheng3. Suppression of c-myc expression by lentiviral vector-mediated- small interfering RNA in Jiyoye cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(4): 80-84.
[3]	PAN Ming-ming,MIAO Hua,HONG Hong,ZHU Zhu-xian. Polystyrene sulfonic lanthanum in the treatment of hyperphosphatemia in rats with chronic renal failure [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(9): 906-909.
[4]	LIU Xin,LI Ying,XU Gong-li,XU Hong-zhi. Significance and expression of Survivin protein in non-Hodgkin's lymphoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(3): 283-285.
[5]	. Correlation of Cathepsin D expression to chemosensitivity of human lymphoma cell lines Raji to Adriamycin [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(7): 37-39.
[6]	WU Depei, CHEN Xiaochen. Current situation and prospect of immunotherapy for lymphoma [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 13-20.